What We’re About
Precision Genetics uses an advanced scientific approach to treating employees and patients. We use healthcare data to determine the risks associated with medications and complex drug regimens. By combining genetic markers, molecular data, and clinical evidence into a comprehensive and actionable solution, we allow busy providers to immediately develop individualized treatment and prevention plans for their patients. This comprehensive, personalized approach reduces interaction and efficacy risks while assuring proper therapy. Our interactive tools empower patients to utilize their molecular results to address their individual risks and treatment pathways based on their unique genetics, demographics, lifestyle, and medical conditions. Most importantly, a patient’s genetic risk analysis can be applied later in life as their risks increase, their health changes or new treatment pathways are identified.
Precision Genetics Employer Wellness solution provides the most comprehensive health and financial wellness platform through innovation and technology. Employers are able to provide their employees and dependants the ultimate healthcare solution by utilizing our medication risk management solution and advanced treatment platform. In addition, we are able to reduce the rising costs of healthcare and pharmacy by deploying a true wellness solution designed for their employee population, employee family members, and covered lives.
Founder and CEO
Nate Wilbourne is the founder and CEO of Precision Genetics. He has a passion for improving the way we deliver healthcare in the US and focuses on disruptive technologies that can impact the standard of care across multiple disciplines. With over 20 years of experience in global healthcare his specialties include: start-ups, venture capital, private equity, sales and marketing for a diverse platform of solutions and services. Nate’s extensive experience in the healthcare industry has allowed him to develop relationships with the nations’ largest healthcare institutions, physician practices and various providers. Prior to starting Precision Genetics, Nate was responsible for client relations, operations, sales and marketing, and business development for multiple healthcare entities including a large division at Stryker Corporation. Nate was a professional basketball player in the NBA and various international teams. He graduated from the University of South Carolina with a BA in Finance in 1997.
Chief Medical Officer
Dr. Wrangle is a medical oncologist and physician scientist who specializes in lung cancer and the development of novel immunotherapies for the treatment of solid tumor malignancies as a faculty member at the University of South Carolina in Charleston. He received fellowship training at Johns Hopkins Hospital in Baltimore, MD where he also completed his post-doctoral training. He has numerous publications of original research. In addition to subspecialty training, Dr. Wrangle trained in the primary care track of the Internal Medicine residency at Emory University in Atlanta, GA. As a thoracic medical oncologist Dr. Wrangle practices in an area of medicine at the forefront of incorporating pharmacogenomic prescribing guidelines into day-to-day practice. Dr. Wrangle brings nearly two decades of research, training, and practice to Precision Genetics and the mission of improving quality-of-care through evidence-based, pharmacogenomic medication management for medical systems and enterprise solutions.
Jeremy Stuart, PhD, MPH
Chief Science Officer
Jeremy has extensive management experience in the life science industries. He specializes in commercial operations, technology development and transfer, manufacturing design, start up and analytical validation of laboratory developed tests (LDTs). Jeremy was part of the senior management team that completed a management buyout of Lab21 Inc. to form Selah Genomics and the subsequent sale of Selah to EKF for $70M (USD). Prior to this, he was a key member of the Agencourt Personal Genomics team, which was acquired by Applied Biosystems for $120M (USD). Jeremy led the development, validation of all of Selah’s molecular assays and led the commercialization and application efforts for next generation sequencing at Life Technologies. While at Agencourt Personal Genomics, Jeremy was a co-developer of the SOLiD next-generation sequencing technology, where he co-authored several patents related to next generation sequencing. Before entering industry, Jeremy completed his postdoctoral work at the Dept. of Genetics & Complex Diseases at the Harvard School of Public Health. Jeremy earned his master’s degree in Toxicology from the University of Minnesota and his doctorate from Harvard University.
Steve Enkemann, PhD
Director of Lab Operations
Dr. Steven Enkemann has a Bachelor’s degree from the University of Michigan, a Master’s degree from Purdue University, and a Doctorate in Molecular Virology from the University of Kentucky. He did his post-doctoral training at the National Cancer Institute where he received an Intramural Research Training Award. Steven is also Board Certified as a Technologist in Molecular Biology by the American Society of Clinical Pathology. His early scientific work involved the regulation of gene expression and the organization of the genome. He went on to join the H. Lee Moffitt Cancer Center where he directed the Molecular Genomics Laboratory. There he participated in numerous clinical studies involving national and international teams evaluating cancer detection, identification, and treatment based on the genomic analysis of tumor samples. He holds patents on the whole genome or transcriptome analysis of cancer and has developed numerous techniques for the classification of tumors and the assessment of malignant potential. Most recently he worked for Selah Genomics using whole genome sequencing technologies to evaluate clinical samples for patients with cancer or heart disease and directed the development of new genome-based assays.
Jay Spencer, MHA, MBA
Chief Strategy Officer & SVP of Finance
Jay Spencer has extensive senior leadership experience across multiple healthcare industry segments from start -ups to multi-billion corporations. With over 16 years of experience in healthcare his expertise includes: health care management, corporate finance, corporate strategy, market research, business development and mergers and acquisitions. In addition, Jay has significant experience in creating impactful go to market corporate strategies and developing strategic partnerships to accelerate value and market share growth in companies.
Prior to joining Precision Genetics, Jay served as VP of Strategy & Finance at Healthcare Solutions a boutique firm which focuses on advising C-suite executives on market strategies, mergers & acquisitions and capital raising strategy. Prior to that Jay was Director of Business Development and Corporate Operations at Diplomat Pharmacy the largest independent Specialty Pharmacy in the US. He also has senior executive leadership experience in the private equity sector where he managed healthcare asset portfolio ($700M) comprising of: PBMs, Pharmacies, Health Plans, Pharma Biotechs, health systems and IT Sass products. As a former healthcare investment banker on Wall Street, Jay has led or contributed in both buy and sell side mergers & acquisitions transactions represented over of $5.2 billion in aggregate value.
Jay received a Master of Health Care Management and a Master of Business Administration with concentration in Corporate Finance & Strategy, from the University of Michigan.
In The News
Have Questions About Us?
Our personalized approach to what we do extends beyond our genetics lab. We, the team, are committed to providing patients, providers, and other labs the quality services and results we put our name behind.